Matija Rijavec (Avtor), Mateja Balantič (Avtor), Anton Lopert (Avtor), Matjaž Fležar (Avtor), Peter Korošec (Avtor)

Povzetek

Background. Asthma treatment response is highly variable and pharmacogenetic markers that predict treatment response would be one step closer to personalized treatment. GWAS studies have shown that polymorphisms GLCCI1 could be associated with asthma treatment response to inhaled corticosteroids (ICS). Materials and methods. We genotyped rs37973 of GLCCI1 in 208 adult asthma patients treated with ICS. Change in % predicted FEV1 was analysed after short-term (3 months) and after long-term (at least 3 years) treatment. Treatment success was defined as good when FEV1 decreased less than 30 ml/year. Results. After 3 months of treatment, change of % predicted FEV1 was higher in patients with GG genotype than in patients with AG+AA genotype, and this genotype dependent difference was only evident in non-smokers. Similar results were found after at least 3 years of treatment when all patients were analysed, in non-smokers and patients with atopy. Even though, no differences in treatment success (good vs. poor response) were observed when analysing the entire group of patients, genotype dependent treatment success was highly influenced by smoking and atopy. GG genotype was overrepresented in non-smokers and patients with atopy with good response. Conclusions. Rs37973 was associated with short- and long-term treatment response; however, there was a great influence of smoking and atopy on pharmacogenetic association. Furthermore, we found GG genotype to be associated with better treatment response, what is contrary to results found in GWAS.

Ključne besede

inhaled corticosteroids;atopy;GLCCI1;FEV1;rs37973;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Založnik: Esmon Publicidad
UDK: 616.2
COBISS: 2048262769 Povezava se bo odprla v novem oknu
ISSN: 1698-0808
Št. ogledov: 761
Št. prenosov: 190
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarne ključne besede: inhalacijski kortikosteroidi;atopija;Asthma;Diagnosis;Therapy;Pharmacogenetics;Polymorphism, genetic;Smoking;Astma;Diagnostika;Terapija;Farmakogenetika;Genetski polimorfizem;Kajenje;
Komentar vira: Soavtorji: Žavbi M, Lopert A, Fležar M, Korošec P; Nasl. z nasl. zaslona; Opis vira z dne 21. 3. 2018;
Strani: str. 165-171
Letnik: ǂVol. ǂ28
Zvezek: ǂiss. ǂ3
Čas izdaje: 2018
DOI: 10.18176/jiaci.0229
ID: 12267616